Redeye returns with an updated take following a solid Q2 report from Stille, showing very minor deviations compared to our estimates. The integration of Fehling is proceeding well and synergies starts showing. We see good prospects for continued growth and for the current stronger margins to persist. Accordingly, we raise our base case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/